Athenex, Inc. (NASDAQ:ATNX) has received an average broker rating score of 2.00 (Buy) from the three analysts that cover the stock, Zacks Investment Research reports. One analyst has rated the stock with a hold rating, one has assigned a buy rating and one has issued a strong buy rating on the company.

Brokerages have set a 1 year consensus price target of $25.73 for the company, according to Zacks. Zacks has also assigned Athenex an industry rank of 105 out of 265 based on the ratings given to its competitors.

ATNX has been the topic of a number of research reports. Deutsche Bank AG initiated coverage on shares of Athenex in a research note on Monday, July 10th. They issued a “buy” rating and a $20.00 price target on the stock. Credit Suisse Group initiated coverage on shares of Athenex in a research note on Monday, September 18th. They issued an “outperform” rating and a $25.00 price target on the stock. Royal Bank Of Canada initiated coverage on shares of Athenex in a research note on Thursday, September 14th. They issued an “outperform” rating and a $35.00 price target on the stock. Laidlaw initiated coverage on shares of Athenex in a research note on Tuesday, September 19th. They issued a “buy” rating and a $36.00 price target on the stock. Finally, J P Morgan Chase & Co initiated coverage on shares of Athenex in a research note on Wednesday, October 18th. They issued a “neutral” rating and a $22.20 price target on the stock.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Goldman Sachs Group Inc. purchased a new position in Athenex in the 2nd quarter worth approximately $601,000. Tudor Investment Corp ET AL purchased a new position in Athenex in the 2nd quarter worth approximately $320,000. OxFORD Asset Management LLP purchased a new position in Athenex in the 2nd quarter worth approximately $956,000. California Public Employees Retirement System purchased a new position in Athenex in the 2nd quarter worth approximately $800,000. Finally, Vanguard Group Inc. purchased a new position in Athenex in the 2nd quarter worth approximately $800,000. 1.10% of the stock is currently owned by institutional investors and hedge funds.

Shares of Athenex (ATNX) traded down 0.35% during trading on Monday, hitting $16.85. The stock had a trading volume of 133,891 shares. The firm’s market cap is $961.51 million. Athenex has a 12-month low of $11.21 and a 12-month high of $20.79. The firm has a 50 day moving average price of $17.46 and a 200 day moving average price of $16.82.

Athenex (NASDAQ:ATNX) last issued its quarterly earnings results on Monday, August 14th. The company reported ($0.88) earnings per share for the quarter. The company had revenue of $4.60 million for the quarter. On average, equities analysts expect that Athenex will post ($2.05) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Athenex, Inc. (ATNX) Receives Consensus Recommendation of “Buy” from Analysts” was reported by Daily Political and is owned by of Daily Political. If you are viewing this piece of content on another publication, it was stolen and republished in violation of international trademark & copyright legislation. The legal version of this piece of content can be read at https://www.dailypolitical.com/2017/10/30/athenex-inc-atnx-receives-consensus-recommendation-of-buy-from-analysts.html.

About Athenex

Athenex, Inc is an oncology pharmaceutical company focused on the development and commercialization of therapies for cancer diseases and supportive therapies. The Company’s technology platform is organized into three categories, including Oral Absorption Platform, Src Kinase Inhibitors and Symptom Therapeutics.

Get a free copy of the Zacks research report on Athenex (ATNX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Athenex (NASDAQ:ATNX)

Receive News & Ratings for Athenex Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athenex Inc. and related companies with MarketBeat.com's FREE daily email newsletter.